Search

Displaying results 2761 - 2770 of 10000 in total
  1. Drug

    Elamipretide

    go.drugbank.com/drugs/DB11981
    ApprovedInvestigational

    [L54036] In September 2025, the U.S. … [A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane.

  2. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    ) to sinus rhythm in adults. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  3. Drug

    Trypsin

    go.drugbank.com/drugs/DB11237
    ApprovedInvestigationalVet approved

    Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. … When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine

  4. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs. … Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.

  5. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  6. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.

  7. Drug

    Quinine

    go.drugbank.com/drugs/DB00468
    ApprovedInvestigational

    An alkaloid derived from the bark of the cinchona tree. … It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633.

  8. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … [L43917] Riltozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineage BA.1.

  9. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    [L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585]

  10. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including

    Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL